The global market for endocrine system drugs is expected to grow at a substantial CAGR of 6.0% during the forecast period (2022-2028). Agents that target a malfunctioning endocrine pathway are known as endocrine drugs. Several chemicals are secreted in or target the nervous system, making them more likely to cause neurologic problems (AEs). The rising prevalence of the endocrine disease is a major factor driving the global endocrine system drugs market. Furthermore, the market is growing as the adolescent population grows, as they are more susceptible to these diseases due to hormonal imbalances. Development of novel drugs for treatment of endocrine disorders is a key factor anticipated to create growth opportunities to the global endocrine system drugs market. The high cost of these drugs and patent expiration of major drugs are some major factors that may restrain the growth of the global endocrine system drugs market.
Impact of COVID-19 Pandemic on Global Endocrine System Drugs Market
The COVID-19 pandemic had negatively impacted the growth of the global endocrine system drugs industry. Cancellation and delay of major endocrine system related surgeries owing to lockdowns imposed by several governments has hampered the growth of the global endocrine system drugs market. However, the market is anticipated to exhibit V-shape recovery during the forecast period.
Segmental Outlook
The global endocrine system drugs market is segmented based on type and application. Based on the type, the market is segmented into diabetes drugs, human growth hormones, and thyroid hormone disorder drugs. Based on the application, the market is sub-segmented into hospitals, clinics, and medical centers.
Global Endocrine System Drugs Market Share by Type, 2021 (%)
Diabetes Drugs held major market share in Global Endocrine System Drugs
Amongst all segments, the diabetes drugs segment held a major market share in 2021 owing to its high prevalence rate. According to the facts supported by WHO, over 285 million people, or 6.4 %of the world’s population, is currently diabetic. Moreover, this segment is anticipated to exhibit the fastest growth during the forecast period owing to development of novel drug therapies and the presence of strong product pipelines in the endocrinology drugs market for the treatment of both types of diabetes mellitus. The unavailability of promising and effective drug products for the treatment of diabetes spurs the growth of this segment.
Regional Outlooks
The global endocrine system drugs market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). Among the regions, the North America held major market share in global endocrine system drugs market; followed by Europe.
Global Endocrine System Drugs Market Growth, by Region 2022-2028
North America Held Considerable Share in the Global Endocrine System Drugs Market
In 2021, North America accounted for a significant portion of the global market for endocrinology drugs. Increased prevalence of endocrine diseases, as well as increased use of hormone replacement therapies and government reimbursement policies, are major contributors to this large share. In addition, the high adoption rate of new technologies and a well-developed healthcare infrastructure are also contributing to its large share.
Market Players Outlook
The major companies serving the global endocrinology system drugs market include Novo Nordisk, Sanofi, Merck, Eli Lilly, AstraZeneca, AbbVie, and others. To compete in the market, market companies are entering various strategies such as mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, which contribute significantly to market growth. For instance, Novartis AG had received FDA approval for Istrusia (osilodrostat) in March 2020. It is an oral tablet used to treat adult Cushing's disease patients who are unable to undergo pituitary gland surgery or who have had surgery but still have the disease.
The Report Covers
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Endocrine System Drugs Market
• Recovery Scenario of Global Endocrine System Drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Novo Nordisk A/S
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Eli Lilly and Company
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Novartis International AG
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Endocrine System Drugs Market by Type
4.1.1. Diabetes Drugs
4.1.2. Human Growth Hormones
4.1.3. Thyroid Hormone Disorder Drugs
4.2. Global Endocrine System Drugs Market by Application
4.2.1. Hospitals
4.2.2. Clinics
4.2.3. Medical Centers
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AbbVie Inc.
6.2. Alacer Corp.
6.3. AstraZeneca Plc
6.4. Eli Lilly Co.
6.5. F. Hoffman La Roche Ltd.
6.6. Facet Biotech Corp.
6.7. Merck Group
6.8. Novo Nordisk A/S
6.9. Sanofi SA
**List not exhaustive**
1. GLOBAL ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ENDOCRINE SYSTEM DIABETES DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL ENDOCRINE SYSTEM HUMAN GROWTH HORMONES DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ENDOCRINE SYSTEM THYROID HORMONE DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL ENDOCRINE SYSTEM DRUGSMARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
6. GLOBAL ENDOCRINE SYSTEM DRUGS FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL ENDOCRINE SYSTEM DRUGS FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL ENDOCRINE SYSTEM DRUGS FOR MEDICAL CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
10. NORTH AMERICAN ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
12. NORTH AMERICAN ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
13. EUROPEAN ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. EUROPEAN ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
15. EUROPEAN ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. REST OF THE WORLD ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. REST OF THE WORLD ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
REST OF THE WORLD ENDOCRINE SYSTEM DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL ENDOCRINE SYSTEM DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL ENDOCRINE SYSTEM DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL ENDOCRINE SYSTEM DRUGS MARKET, 2022-2028 (%)
4. GLOBAL ENDOCRINE SYSTEM DRUGS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL ENDOCRINE SYSTEM DIABETES DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL ENDOCRINE SYSTEM HUMAN GROWTH HORMONES DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL ENDOCRINE SYSTEM DRUGS MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
8. GLOBAL ENDOCRINE SYSTEM DRUGS FOR HOSPITALS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL ENDOCRINE SYSTEM DRUGS FOR CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL ENDOCRINE SYSTEM DRUGS FOR MEDICAL CENTERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL ENDOCRINE SYSTEM DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. US ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
13. CANADA ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
14. UK ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
15. FRANCE ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
16. GERMANY ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. ITALY ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. SPAIN ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. REST OF EUROPE ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. INDIA ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. CHINA ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. JAPAN ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. SOUTH KOREA ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. REST OF ASIA-PACIFIC ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF THE WORLD ENDOCRINE SYSTEM DRUGS MARKET SIZE, 2021-2028 ($ MILLION)